EHA 2019: Dr. Susan O’Brien on Frontline Therapy in CLL Dr. Susan O’Brien moved from MD Anderson to head up the CLL research and clinical team at the University of...
Vaccines for CLL Patients The US CDC ACIP (Center for Disease Control - Advisory Committee on Immunization Practices) provides specific vaccine recommendations for people with...
Things to Know About Idelalisib By Tom Henry – CLL Patient and Pharmacist Idelalisib (eye-del-a-lis-ib), which is marketed under the tradename of Zydelig® in the United...
New Formulation of Imbruvica (ibrutinib) – Commentary Dr. Furman has been involved in the development of ibrutinib since its very earliest trials. This discussion was triggered by the...
Things to Know About Venetoclax When most of us think of a pharmacist we think of them primarily in the role of retail pharmacy, the...
One Man’s Opinion: Dr. Rick Furman on the Diminished Role of FCR in treating CLL Dr. Rick Furman of Weill-Cornell answers your questions in our ASK THE DOCTOR feature in our quarterly newsletters, responds to...
Things to Know About Ibrutinib By Tom Henry – CLL Patient and Pharmacist Ibrutinib (eye-broo-ti-nib), which is marketed under the tradename of Imbruvica® in the...
The Role of the Pharmacist in CLL When most of us think of a pharmacist we think of them primarily in the role of retail pharmacy, the...
Steroids: Short-Term Use and the Increased Risk of Serious Complications: Correlation versus Causation (Part 3) Introduction This is the last of a three-part series on the risks and benefits of steroids in CLL. This section reviews a...
Steroids: The Downside (Part 2) In the first of our three part series on the use of steroids in CLL, I explained what corticosteroids are...
